Cargando…

Predictors of Early Thrombotic Events in Adult Patients with Acute Myeloid Leukemia: A Real-World Experience

SIMPLE SUMMARY: The reported incidence of thrombotic events (TE) in non-promyelocytic acute myeloid leukemia (AML) patients varies in the literature from 2% to 13%. The aim of our retrospective study was to assess the incidence of TE in a real-word population of AML patients to determine the impact...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paterno, Giovangiacinto, Palmieri, Raffaele, Forte, Vittorio, Del Prete, Valentina, Gurnari, Carmelo, Guarnera, Luca, Mallegni, Flavia, Pascale, Maria Rosaria, Buzzatti, Elisa, Mezzanotte, Valeria, Cerroni, Ilaria, Savi, Arianna, Buccisano, Francesco, Maurillo, Luca, Venditti, Adriano, Del Principe, Maria Ilaria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688263/ https://www.ncbi.nlm.nih.gov/pubmed/36428732 http://dx.doi.org/10.3390/cancers14225640

Ejemplares similares

Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML
por: Meddi, Elisa, et al.
Publicado: (2023)

Fever of Unknown Origin and Multidrug Resistant Organism Colonization in AML Patients
por: Guarnera, Luca, et al.
Publicado: (2023)

In BCR-ABL1 Positive B-Cell Acute Lymphoblastic Leukemia, Steroid Therapy Induces Hypofibrinogenemia
por: Buzzatti, Elisa, et al.
Publicado: (2022)

Time for Dynamic Assessment of Fitness in Acute Myeloid Leukemia
por: Palmieri, Raffaele, et al.
Publicado: (2022)

Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness
por: Palmieri, Raffaele, et al.
Publicado: (2020)

Therapy-related Myeloid Neoplasms: Considerations for Patients’ Clinical Evaluation
por: Palmieri, Raffaele, et al.
Publicado: (2023)

Case report: A Saprochaete clavata (Magnusiomyces clavatus) severe infection effectively treated with granulocyte transfusion in a young patient with myeloid sarcoma
por: Pasqualone, Gianmario, et al.
Publicado: (2022)

Real-life experience of secondary prophylaxis with DOACs in splanchnic venous thrombosis during COVID-19 pandemic
por: Guarnera, Luca, et al.
Publicado: (2023)

Pulmonary function testing for fitness assessment in asymptomatic adults with newly diagnosed acute myeloid leukemia
por: Palmieri, Raffaele, et al.
Publicado: (2022)

PB1835: THE ISTH-DIC SCORE PREDICTS 30-DAYS OUTCOME IN NON-M3 ACUTE MYELOID LEUKEMIA PATIENTS
por: Paterno, G., et al.
Publicado: (2022)

Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial
por: Buccisano, Francesco, et al.
Publicado: (2022)

NK Cell Inflammation in the Clinical Outcome of Colorectal Carcinoma
por: Coppola, Andrea, et al.
Publicado: (2015)

Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation
por: Buccisano, Francesco, et al.
Publicado: (2021)

Can Polycythemia Vera Evolve from Acute Myeloid Leukemia? Report of a Case Showing a Simultaneous Minor JAK2 V617F Mutated Clone
por: Borsellino, Beatrice, et al.
Publicado: (2022)

Diagnostic Performance and Safety of Bronchoalveolar Lavage in Thrombocytopenic Haematological Patients for Invasive Fungal Infections Diagnosis: A Monocentric, Retrospective Experience
por: Cefalo, Mariagiovanna, et al.
Publicado: (2019)

Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications
por: Del Principe, Maria Ilaria, et al.
Publicado: (2016)

FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance
por: Caratelli, Sara, et al.
Publicado: (2017)

ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol
por: Buccisano, Francesco, et al.
Publicado: (2022)

The Venetoclax/Azacitidine Combination Targets the Disease Clone in Acute Myeloid Leukemia, Being Effective and Safe in a Patient with COVID-19
por: Cristiano, Antonio, et al.
Publicado: (2022)

Treatment of Acute Myeloid Leukemia with 20–30% Bone Marrow Blasts
por: Maurillo, Luca, et al.
Publicado: (2013)

Treatment of Low-Blast Count AML using Hypomethylating Agents
por: De Bellis, Eleonora, et al.
Publicado: (2017)

Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy
por: Sarlo, Chiara, et al.
Publicado: (2013)

Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage
por: Arriga, Roberto, et al.
Publicado: (2015)

Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy
por: Del Principe, Maria Ilaria, et al.
Publicado: (2014)

Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia
por: Aureli, Anna, et al.
Publicado: (2021)

The effect of COVID-19 on the frequency of Pneumocystis jirovecii pneumonia: a monocentric, retrospective, and observational study
por: Del Prete, Valentina, et al.
Publicado: (2023)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

Reliability of flow-cytometry in diagnosis and prognostic stratification of myelodysplastic syndromes: correlations with morphology and mutational profile
por: Guarnera, Luca, et al.
Publicado: (2023)

Clinical significance of occult central nervous system disease in adult acute lymphoblastic leukemia: a multicenter report from the Campus ALL Network
por: Del Principe, Maria Ilaria, et al.
Publicado: (2019)

Characterization of FLT3-ITD(mut) acute myeloid leukemia: molecular profiling of leukemic precursor cells
por: Travaglini, Serena, et al.
Publicado: (2020)

Lack of efficacy of imiquimod in patients with basal cell carcinoma previously treated with rituximab for B cell lymphoma: two case reports
por: Campione, Elena, et al.
Publicado: (2016)

P499: APPLICABILITY OF 2022 CLASSIFICATIONS OF ACUTE MYELOID LEUKEMIA IN THE REAL-WORLD SETTING
por: Attardi, Enrico, et al.
Publicado: (2023)

Atypical Rearrangements in APL-Like Acute Myeloid Leukemias: Molecular Characterization and Prognosis
por: Guarnera, Luca, et al.
Publicado: (2022)

Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting
por: Attardi, Enrico, et al.
Publicado: (2023)

Direct CD32 T-cell cytotoxicity: implications for breast cancer prognosis and treatment
por: Sconocchia, Giuseppe, et al.
Publicado: (2022)

Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry
por: Agosti, Pasquale, et al.
Publicado: (2023)

P505: GIMEMA AML1819 TRIAL: GEMTUZUMAB OZOGAMICIN PLUS INTENSIVE CHEMOTHERAPY IMPACTS ON THE LEVEL OF POST-CONSOLIDATION MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA
por: Venditti, Adriano, et al.
Publicado: (2023)

Measuring Biomechanical Risk in Lifting Load Tasks Through Wearable System and Machine-Learning Approach
por: Conforti, Ilaria, et al.
Publicado: (2020)

Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide
por: Gurnari, Carmelo, et al.
Publicado: (2022)

SARS-CoV-2 vaccination and thrombotic risk in myeloproliferative neoplasms
por: Borsani, Oscar, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ekf2od522lphr3omn8micqfuna